Johnson & Johnson
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JNJ.MX | JNJ.NE | LLY.NE | MRK | AZN.L | 4552.T | |
|---|---|---|---|---|---|---|
| Market cap | 12.39T | 915.54B | 1.74T | 370.96B | 217.84B | 64.55B |
| P/E (TTM) | 44.2 | 25.4 | 65.7 | 151.9 | 26.7 | — |
| Forward P/E | — | — | — | 16.7 | 16.6 | 14.4 |
| Price/book | 8.1 | 0.8 | 1.4 | 8.9 | 5.6 | 1.6 |
| Dividend yield | 1.96% | 2.49% | 0.58% | 2.26% | 1.70% | 3.97% |
| 1-year change | +47.64% | +40.84% | +35.37% | +75.29% | +9.27% | −17.24% |
| Today | +2.16% | +4.32% | +0.78% | +3.93% | +0.16% | +4.96% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All JNJ.MX news ›Johnson & Johnson Stock (JNJ) Moved Up by 3.54% on Nov 4: A Full Analysis
Johnson & Johnson (JNJ) moved up by 3.54%. The Pharmaceuticals & Medical Research sector is up by 2.60%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Eli Lilly and Co (LLY) up 1.04%; AbbVie Inc (ABBV) up…
If Johnson & Johnson Stock Looks Expensive, You Need To Read This
What Johnson & Johnson Costs On The Profit Ahead The Growth Johnson & Johnson Has To Deliver Looking ahead to fiscal 2027, the consensus forecast points to revenue growing 6.6%, compared to the 7.8% Johnson & Johnson delivered over the…
The Sunset of Legacy Patents and the Rise of New Waves: Multinational Pharma Q3 Financials and Clinical Strategies
geneonline.com The Sunset of Legacy Patents and the Rise of New Waves: Multinational Pharma Q3 Financials and Clinical Strategies GO Prime with only $1.49 now
Johnson Controls Drops 6.5%, Erasing About $5 Billion in One Session
As seen on the 24/7 Wall St. homepage on November 4, 2026. A 6.5% slide to $138.26 lops roughly $5 billion off an $83.7 billion building-systems giant, a rare single-session hit for a name this size. Whether it holds above the open of…
Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcript
Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call November 4, 2026 7:00 AM EST Deepak Nath - CEO & DirectorPierre Palassian - Interim CFO, Senior VP of Finance & Group Controller Welcome, everyone, and thank you for joining the Smith &…
AMETEK, Eaton and Dover Are Delivering Record Results. Can Their Dividends Keep Growing?
Order books at three industrial giants just hit records, and their dividends have grown every single year for over a decade. The real question is whether the debt piling up behind those records puts future raises at risk. AMETEK pays $0.34…
If a Stock Market Crash Comes in November, You'll Still Rest Easy Knowing You Bought This Dividend Stock
This snack maker shouldn't see demand falter during poor economic times. You don't have to be someone who believes in doom and gloom to know that a stock market crash will come. After all, it's just a matter of time. Of course, while…
Hershey Trades 21% Below Its Historical P/E. Here Are 2 More Dividend Stocks
Blue-chip dividend payers rarely go on sale, but three household names now trade below their long-run earnings multiples while still covering their payouts with room to spare. The question is whether the market is handing income investors…
GlaxoSmithKline Pharmaceuticals NSE:GLAXO Analyst Meet 2026
Kalkine India GlaxoSmithKline Pharmaceuticals (NSE:GLAXO): What Did the Analyst Meet Recording Disclose? Source: Krish Capital Pty Ltd GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) submitted a regulatory filing on 4 November 2026, di
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com145
- seekingalpha.com63
- themarketsdaily.com43
- defenseworld.net40
- 247wallst.com39
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.